Preferences help
enabled [disable] Abstract
Number of results
2012 | 84 | 8 | 377-382
Article title

Metalloproteinase 2 and 9 Activity in the Development of Pancreatic Cancer

Title variants
Languages of publication
Pancreatic adenocarcinoma is the fourth most common cancer occurring in both women and men. In Poland, within the past ten years the number of deaths from pancreatic cancer increased by 29%.The aim of the study was to determine the correlation between the activity of metalloproteinase (MMP) 2 and 9 and progression and aggressiveness of pancreatic cancer.Material and methods. Tissue samples were collected from 36 patients with diagnosed pancreatic adenocarcinoma who underwent Whipple resection. Tumor tissues were analyzed by gel zymography, zymography in situ and immunohistochemistry.Results. The activity of MMPs was found mainly in cancer cells. Active form of MMP2 (62 kDa) was present in 88% of cases and MMP9 (83 kDa) in 38% of cases. By contrast, immunohistochemical staining revealed the presence of metalloproteinase 9 in all studied tissues. MMP activity was assessed against histological grade of the tumor. In the case of group G1 there was no activity of matrix metalloproteinase 9. By comparing the activity we concluded that the activity of MMPs in tumors with the highest degree of differentiation is significantly lower than in G2 and G3. Metalloproteinase 9 expression analysis revealed no significant differences between the groups of various degrees of histological maturity. The level of expression did not differ between the groups N0 and N1.Conclusion. Lack of metalloproteinase 9 activity in group G1 may indicate that MMP9 is activated only in higher tumor grades. We have shown that an active form of MMP2 is found in all histological grades, which supports its involvement in the development of pancreatic cancer. Metalloproteinases are attractive target of anticancer therapy but not only the level of expression of metalloproteinases should be taken into account but also their level of activity and factors associated with their activation.
Physical description
1 - 8 - 2012
17 - 9 - 2012
  • Department of Surgical Research and Transplantology, Medical Research Centre Polish Academy of Sciences in Warsaw
  • Raporty na podstawie danych Centrum Onkologii
  • Singh P, Srinivasan R, Dev Wig J: Major Molecular Markers in Pancretic Ductal Adenocarcinoma and Their Roles in Screening, Diagnosis, Prognosis and Treatment, Pancreas 2011; 40: 644-52.[WoS][Crossref]
  • Neoptolemos JP, Urrutia RA, Abbruzzese J et al.: Pancreatic cancer. Springer 2010.
  • Egebald M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002; 2:161-74.[Crossref]
  • Sullu Y, Demirag GG, Yildirim A et al.: Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract 2011; 207: 747-53.
  • Koyama H, Iwata H, Kuwabara Y et al.: Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymography. Eur J Cancer 2000; 36: 2164-70.[Crossref]
  • Ellenrieder V, Alber B, Lacher U et al.: Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000; 85:14-20.[Crossref]
  • Jones L, Humphreys M et al.: Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer: Increased Expression of Matrix Metalloproteinase-7 Predicts Poor Survival. Clin. Cancer Res 2004; 10: 2832-45.[Crossref]
  • Nakamura T, Kuwai T, Kim J et al.: Stromal Metalloproteinase-9 Is Essential to Angiogenesis and Progressive Growth of Orthotopic Human Pancreatic Cancer in Parabiont Nude Mice1. Neoplasia 2007; 9: 979-86.[WoS]
  • Matsuyama Y, Takao S, Aikou T: Comparison of Matrix Metalloproteinase Expression Between Primary Tumors With or Without Liver Metastasis in Pancreatic and Colorectal Carcinomas. J Surg Oncol 2002; 80: 105-10.
  • Yokoyama M: Matrix Metalloproteinase-2 in Pancreatic Juice for Diagnosis of Pancreatic Cancer. Pancreas 2002; 24: 344-47.[PubMed][Crossref]
  • Gialeli Ch, Theocharis A, Karamanos N: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting, 2011. FEBS Journal 2011; 278: 16-27.[WoS]
  • H. Braat et al.: Pancreatic cancer: Promise for personalised medicine? Cancer Lett 2011; in press.[WoS]
  • Collisson EA, Sadanandam A, Olson P et al.: Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Medicine 2011; 17: 500-04.[WoS][Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.